Development of safe and immunogenic reassortant viruses with 5:3 ...
Development of safe and immunogenic reassortant viruses with 5:3 ...
Development of safe and immunogenic reassortant viruses with 5:3 ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Reassortant LAIV in Russia<br />
> 30 years on the Market;<br />
> 100 million doses produced;<br />
Effectiveness <strong>of</strong> LAIV for adults (summary from 126 trials : 500 to 45,000<br />
adults per trial; total > 500,000 adults):<br />
• Effectiveness was confirmed for each trial.<br />
• Mean effectiveness for 126 trials was 1.80 (= 45%).<br />
• Index <strong>of</strong> effectiveness was 1.5 (= 33%), even when epidemics were<br />
caused by new antigenic variants not presented in LAIV.<br />
Nevertheless, new approaches to improve LAIV <strong>immunogenic</strong>ity <strong>and</strong><br />
effectiveness are <strong>of</strong> great interest<br />
2 <strong>of</strong> 16
Change language